Kamada Ltd KMDA
Kamada Ltd (Nasdaq: KMDA) is an infectious disease drug developer. Its lead program, KEDRAB (rabies immune globulin), is in Phase 3 for rabies post-exposure prophylaxis. Its next catalyst on record is Normal source plasma: start of NSP sales (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Normal source plasma — start of NSP sales (H2 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| KEDRAB | rabies | biologic-other | Approved |
| GLASSIA | alpha-1 antitrypsin deficiency | protein/peptide | Approved |
| CYTOGAM | CMV prophylaxis | biologic-other | Approved |
| WINRHO SDF | ITP / Rh isoimmunization | biologic-other | Approved |
| VARIZIG | varicella zoster post-exposure | biologic-other | Approved |
| HEPAGAM B | hepatitis B | biologic-other | Approved |
| Inhaled AAT | AATD (orphan designation US and EU) | protein/peptide | Phase 3 |
Recent results and decisions
- Dec 8, 2025negative Prespecified interim futility analysis found Phase 3 InnovAATe unlikely to show a significant benefit in FEV1; trial discontinued, no safety concerns.
the Phase 3 InnovAATe trial of Inhaled AAT for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) is unlikely to demonstrate a statistically significant benefit in its primary endpoint - lung function measured by FEV1.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 infectious disease companies
- Gilead Sciences, Inc. GILD
- GSK plc GSK
- Moderna, Inc. MRNA
- Vaxcyte, Inc. PCVX
- Vir Biotechnology, Inc. VIR
- Novavax Inc NVAX
- Sinovac Biotech Ltd SVA
- CorMedix Inc. CRMD
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.